To register for the web conference, please sign up using the following link: https://attendee.gotowebinar.com/register/5303405709530509661

The number of spots is limited, so we recommend registering well in advance to secure your spot.

A recording of the web conference will be available on the company's website www.chordate.com and on the Västra Hamnen Corporate Finance YouTube channel after the conference concludes.

The presentation can be viewed through the following link: https://www.finwire.tv/webcast/chordate-medical/q2-2023/

Following the presentation, there will be a Q&A session where viewers can submit questions.

A recording of the presentation will be made available afterwards on the company's website http://www.chordate.com and on Finwire TV's YouTube channel.

“This is a pivotal step, and once the scientific article is published, it will be a valuable tool for the company in marketing and sales efforts. Additionally, the article will be an important basis in upcoming reimbursement processes," says Anders Weilandt, CEO of Chordate Medical.

Chordate Medical will announce when the authors have received approval for publication in the journal in question.

The final results from Chordate Medical's PM007 study demonstrate that the company's migraine treatment, K.O.S, exhibits a significant reduction in the number of headache days and migraine days in adult patients with moderate to severe chronic migraine. The results also show that K.O.S maintains a sustained therapeutic effect and is well-tolerated, with few unexpected side effects. This sets apart the unique treatment, which is non-pharmaceutical, from other preventative treatments in the market, also due to its favorable side effect profile.

The IHC 2023 congress is organized every other year by the International Headache Society, IHS, in various locations around the world. This time, it is in Seoul, Korea, which is the first time the event has been held in Asia since 2005.

“The interest in the study and its results is significant within the migraine field. Being part of this congress is an excellent opportunity for us to inform about K.O.S as a treatment method to the absolute forefront of the migraine field worldwide," says Anders Weilandt, CEO of Chordate.

IHS is an international professional organization based in the UK that collaborates with others to benefit individuals affected by headache disorders. As a charity, the purpose of IHS is to advance headache science, education, and management, and to promote headache awareness worldwide.

More information about the congress: https://ihc2023.org/
More information about IHS: https://ihs-headache.org/en/

“The case study is a good example of a migraine patient who, for various reasons, cannot medicate with drugs typically prescribed for chronic migraines, and who experiences a very positive effect from K.O.S. A reduction from 18 to 8 migraine days per month, combined with a four-month sustained effect, is a significant positive outcome. It demonstrates the great potential of K.O.S. as a new treatment option for individuals suffering from chronic migraines and who do not respond to other existing treatments," says Jan Hermansson, Clinical Research & Medical Director at Chordate Medical, who was present in Berlin.

The case study was authored by Florian Rimmele together with Tim P. Jürgens and Peter Kropp at the Department of Neurology, Headache Center North-East, University Medical Center Rostock. Below is an excerpt from the case study:

A 45-year-old female patient with a long history of chronic migraine with visual auras presented to our headache center. In addition to systemic mastocytosis with evidence of a KIT-D816V mutation, the patient suffers from bronchial asthma, recurrent depression, and anxiety disorder. On average, the patient had migraine on 18 days/month. Due to mastocytosis and allergic reaction to multiple substances, acute medication was only possible with tramadol, which showed only moderate effect. The established medicinal migraine prophylactics could not be used because of various contraindications; the patient reacted allergically to the considered amitriptyline and also the multiple injections of a prophylaxis with onabotulinumtoxinA are contraindicated in mastocytosis.

The patient received kinetic oscillatory stimulation (K.O.S.) in a double-blind, randomized placebo-controlled trial. Over 6 weeks, weekly stimulation of 10 minutes per nostril was given, under which the migraine improved very well and a reduction to an average of 8 migraine days/month was achieved. The patient reported no side effects during the stimulation therapy. After completion of the study and unblinding, the patient could be assigned to the test (verum) group. The improvement effect lasted for 4 months.

Conclusion
In this particular case, established migraine prophylactic medication was not possible in a patient with chronic migraine, due to her other medical conditions, especially systemic mastocytosis. K.O.S., which was performed as part of a study, proved to be a well-tolerated and long-lasting prophylactic.